Evaluation of Thrombocytopenia in Hematological Malignancies
Journal of Pharmaceutical Research International,
Thrombocytopenia is defined as platelet count < 1.5 lakhs/cumm. It is the commonest platelet abnormality observed in clinical practice with different clinical expression. Thrombocytopenias in hematological malignancies are clonal proliferations of the malignant hematopoietic stem cells characterized by the accumulation of blasts principally in the marrow at the cost of impaired production of normal blood cells. The aim of the present study was to evaluate thrombocytopenia in cases of hematological malignancies with study of clinical profile and laboratory parameters in patients with thrombocytopenia. The present study had maximum numbers of patients were in the age group 20-39 years (8 cases). Patients with platelet count more than 150 x 109/L, patients presented with massive hemorrhage, and who received massive colloid or crystalloid transfusion for volume loss are not included in our study. The maximum number of patients presenting with thrombocytopenia were males (18 cases). It was concluded that chronic lymphocytic leukemia are more common than other hematological malignancy cases.
- hematological malignancies
- platelet count.
How to Cite
Werlhof PG. Disquisitio medica et philologica de variolis et anthracibus. Sumptibus haeredum Nicolai Foersteri et Filii; 1735.
Balduini CL, Melazzini F. Research at the heart of hematology: Thrombocytopenias and platelet function disorders. Haematologica. 2017;102(2):203.
Stasi R. How to approach thrombocytopenia. ASH Education Program Book. 2012;2012(1):191-7.
Purohit A, Aggarwal M, Singh PK, et al. Re-evaluation of need for bone marrow examination in patients with isolated thrombocytopenia contributors. Indian J Hematol Blood Transfus. 2016;32: 193–196.
Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012;2012:191–197.
Abstract View: 431 times
PDF Download: 208 times